IONS Stock: Price, Earnings History and SEC Filings
Ionis Pharmaceuticals, Inc. (IONS) last traded at $43.52, down 1.96% on the latest session and down 2.5% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.70 against an analyst estimate of $-1.09, a beat of 35.8%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
IONS earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 29, 2026 | $-0.70 | $-1.09 | +35.78% |
| Mar 2026 | Apr 29, 2026 | $-0.56 | $-0.89 | +37.08% |
| Dec 2025 | Feb 25, 2026 | $-1.41 | $-1.31 | -7.63% |
| Sep 2025 | Oct 29, 2025 | $-0.80 | $-1.23 | +34.96% |
IONS beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How IONS reacts to earnings
Across its last 8 earnings releases, IONS moved 3.0% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-07-29 | Before open | -2.28% |
| 2026-04-29 | Before open | +4.25% |
| 2026-02-25 | Before open | -5.29% |
| 2026-01-12 | Before open | +1.69% |
| 2025-10-29 | Before open | -2.30% |
| 2025-07-30 | Before open | +4.56% |
| 2025-04-30 | Before open | +3.02% |
| 2025-02-19 | Before open | -0.44% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
IONS financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $944M | -$381M | -$320M | -40.4% | $-2.38 |
| 2024 | $705M | -$454M | -$546M | -64.4% | $-3.04 |
| 2023 | $788M | -$366M | -$331M | -46.5% | $-2.56 |
| 2022 | $587M | -$270M | -$290M | -45.9% | $-1.90 |
| 2021 | $810M | -$29M | $19M | -3.5% | $-0.20 |
| 2020 | $729M | -$444M | $772000 | -60.9% | $-3.18 |
| 2019 | $1.1B | $278M | $315M | 24.8% | $1.90 |
| 2018 | $600M | $274M | $589M | 45.6% | $2.07 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for IONS
- 8-K · Oct 23, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Oct 21, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Sep 23, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Sep 4, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Sep 4, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 10-Q · Jul 29, 2026
- 8-K · Jul 29, 2026Results of operations, Financial statements and exhibits
- 8-K · Jul 10, 2026Regulation FD disclosure, Financial statements and exhibits
- 8-K · Jul 9, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Jun 24, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
Insider filing activity
IONS insiders filed 6 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
IONS news
- What Just Happened To Alnylam Stock?Oct 30, 2026 · trefis.com
- Alnylam Sinks 19% as It Expands Nucresiran Heart Trial Again, Citing “A High Level of Conviction”Oct 29, 2026 · tikr.com
- ARS Pharmaceuticals, Inc. (SPRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseOct 29, 2026 · finance.yahoo.com
- Earnings Preview: Ionis Pharmaceuticals (IONS) Q3 Earnings Expected to DeclineOct 28, 2026 · finance.yahoo.com
- NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues MissOct 27, 2026 · finance.yahoo.com
- Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)Oct 23, 2026 · finance.yahoo.com
- Ionis ranked #1 on Science’s Top Employers listOct 22, 2026 · finance.yahoo.com
- Ionis Pharmaceuticals Secures FDA Orphan Drug Designation For Rare Epilepsy TreatmentOct 22, 2026 · stocktwits.com
About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. (IONS) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in CA. Its fiscal year ends in December.